In this What's It Worth? For Everyone episode, we're asking: Are we waiting too long for new treatments?

If you've ever heard about a promising new medication, peptide, or breakthrough therapy and wondered, "If it works so well, why isn't everyone using it yet?"—you're not alone.

It can feel frustrating to hear about exciting discoveries while waiting years before they become part of routine healthcare.

In this episode, we take you behind the scenes of the scientific process to explore what happens between an exciting idea and a treatment that is recommended for patients. Along the way, we use recent blood thinner research as a real-world example of why asking the right questions—and taking the time to answer them—matters.

• A promising scientific idea is not the same as a proven treatment.

• Clinical trials help researchers answer two critical questions: Does it work? and Is it safe?

• Many exciting discoveries change as they are studied in larger groups of people.

• The goal of the scientific process is not to slow innovation—it is to help ensure new treatments provide meaningful benefits while minimizing harm.

• Progress in medicine depends on both curiosity and careful testing.

Use these questions to help guide conversations with your healthcare team when you hear about a new treatment:

• How strong is the evidence supporting this treatment?

• Has it been studied in people, or only in laboratory or animal studies?

• What are the known benefits?

• What are the known risks?

• How does it compare with treatments that are already available?

• Is this treatment appropriate for someone with my medical history?

New discoveries are exciting—and they are how medicine moves forward. But every promising idea deserves careful testing before it becomes routine care.

The goal isn't simply to bring new treatments to patients faster. It's to bring forward treatments that have been shown to make a meaningful difference in people's lives.

This episode is for educational purposes only and is not medical advice. It does not replace care from your own healthcare team.

🎙️Host: Diana Langworthy, PharmD, BCPS | Associate Professor at the University of Minnesota College of Pharmacy | Clinical Pharmacist in Adult Internal Medicine, Fairview East Bank Hospital

📬 Enjoyed this episode? Find more evidence-based content, podcast episodes, social media, and ways to connect at https://beacons.ai/diana.the.pharm.d.etective.

In this What's It Worth? For Everyone episode, we're talking about AFib, blood thinners, and liver disease.

AFib stands for atrial fibrillation. It is a common heart rhythm problem that can increase the risk of stroke. Because of that stroke risk, many people with AFib are prescribed a blood thinner.

But what if someone has AFib and also has liver disease or cirrhosis?

That decision can be more complicated.

In the full What's It Worth? episode, we discussed a systematic review and meta-analysis comparing DOACs with warfarin in people with atrial fibrillation and liver disease. DOACs are a group of blood thinners that include apixaban, also known as Eliquis, and rivaroxaban, also known as Xarelto.

Key Takeaways

• In this study, DOACs appeared to work similarly to warfarin for preventing stroke in people with AFib and liver disease.
• DOACs also appeared to have a more favorable bleeding profile than warfarin in many patients, including patients with cirrhosis.
• This episode explains why blood thinner decisions in liver disease are not one-size-fits-all.
• We talk about how liver function, kidney function, bleeding history, clotting risk, and other medications can all affect which blood thinner may be the safest choice.
• The core takeaway from the review is that DOACs may be reasonable options for many people with AFib and liver disease, but the decision still needs to be individualized.
• Practical takeaway: Bring your full medication list to your appointment and ask your healthcare team how your liver disease, kidney function, age, weight, bleeding risk, and other medicines affect the blood thinner choice.

Questions Worth Asking

Use these questions to help guide a conversation with your healthcare team:

• Why do I need a blood thinner?
• What is my risk of stroke if I do not take one?
• What is my personal risk of bleeding?
• How severe is my liver disease?
• Is this blood thinner safe for my level of liver function?
• How is my kidney function?
• Are any of my medicines raising my bleeding risk?
• Are any of my medicines interacting with this blood thinner?
• What bleeding symptoms should I watch for?
• Who should I call if I notice bleeding or need a procedure?

Bring your full medication list to your appointment. This includes prescription medicines, over-the-counter medicines, pain relievers like ibuprofen or naproxen, aspirin, vitamins, supplements, and medicines you only take once in a while.

Having liver disease or cirrhosis does not automatically mean a person with AFib can never take a blood thinner. But it does mean the decision needs extra care.

The goal is thoughtful, personalized care.

This episode is for educational purposes only and is not medical advice. It does not replace care from your own healthcare team.